Philippe JEAN-PIERRE

---

• Type de publi. : Ouvrage (y compris édition critique et traduction)
• Date de publi. : 01/01/1999
• Auteurs : Rémy KnafouPhilippe Duhamel
• Organismes : Espaces et Sociétés

---

Résumé : L’État de la géographie. Autoscopie d’une science. Rémy Knafou (dir.), coordination de la partie 2 : « La communauté des géographes », composée de huit articles rédigés par Gérard Joly, Henry Chamussy, Christian Daudel, Denise-Douzant-Rosenfeld, Jean Raison, Jean-Pierre Raison et Michel Sivignon.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/01/1999
• Auteurs : Stéphane GallandFrédéric GrimaudPhilippe BeauneJean-Pierre Campagne
• Organismes : Département Méthodes Scientifiques pour la Gestion Industrielle Département Méthodes Scientifiques pour la Gestion Industrielle Département Systèmes Multi-Agents Département Méthodes Scientifiques pour la Gestion Industrielle

---

Résumé : We work in complex industrial system simulation on geographical, decisional and informational distribution terms. We postulate that existing methodologies and simulation tools seldom take account of these three distribution aspects. Our goal is to conceive a modeling and simulation solution that is able to utilize these aspects to resolve problems. This paper is divided into 4 parts. The first is a brief introduction. The second is a short resume of the state of the art in the distributed simulation and the multi- gent system fields. There, we present the bases used for our reasoning. The second part describes the industrial system distribution modeling problems. In this section, we also develop the methological multi-agent approach. Thus the use of distributed simulation, economical and multi-agent works enable us to consider a model on which is based our approach. Throughout in this section, we present an iterative construction approach of our methodology and simulation environment. Finally, we conclude.

---

Fichiers liés : grimaud_1999.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/1999
• Auteurs : Jean-Philippe SteyerPierre BuffièreD. RollandRenatto Moletta
• Organismes : Laboratoire de Biotechnologie de l'Environnement [Narbonne] Laboratoire de Biotechnologie de l'Environnement [Narbonne] Laboratoire de Biotechnologie de l'Environnement [Narbonne] Laboratoire de Biotechnologie de l'Environnement [Narbonne]
• Publié dans Water Research le 24/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/01/1999
• Auteurs : Pierre CabanesBashkim VrekajJean-Luc LamboleyPhilippe LenhardtClaire BalandierGuillaume BonnetVangjel DimoJulien EspagneÉric FouacheLami KoçoSkënder MuçajPellumb NaipiPatrick NeuryYann PépinIris PojaniFrançois QuantinAltin Skenderaj
• Organismes : Institut national de recherches archéologiques préventives
• Publié dans Bulletin de Correspondance Hellénique le 26/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/1998
• Auteurs : Jean-Pierre TeyssierPhilippe BouysseZineb OuarchDenis Barataud
• Organismes : Institut de Recherche en Communications Optiques et Microondes Institut de Recherche en Communications Optiques et Microondes Institut de Recherche en Communications Optiques et Microondes Institut de Recherche en Communications Optiques et Microondes
• Publié dans IEEE Transactions on Microwave Theory and Techniques le 31/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/1998
• Auteurs : Danielle Casset-SenonPhilippe LaurentDominique BabutyVéronique EderLaurent FauchierJean Paul FauchierJean Marie PottierPierre Cosnay
• Organismes : Centre Hospitalier Régional Universitaire de Tours Pôle Santé Léonard de Vinci [Chambray-lès-Tours] Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours
• Publié dans American Journal of Cardiology le 22/10/2020

---

Résumé : To evaluate the diagnostic performance of Fourier phase analysis of gated blood pool single-photon emission computed tomography (GBP SPECT) in arrhythmogenic right ventricular (RV) cardiomyopathy, 18 patients with confirmed arrhythmogenic RV cardiomyopathy underwent GBP SPECT and x-ray cineangiography. Results were compared with data obtained with GBP SPECT in 10 control subjects. This 3-dimensional method demonstrated good correlation with cineangiography for measurements of RV enlargement and extent of the disease; RV and left ventricular segments were analyzed with the same accuracy. Tomographic abnormalities were significant decreased RV ejection fraction, RV dilatation, nonsynchronized contraction of the ventricles, increased RV contraction dispersion, presence of segmental RV wall motion disorders and/or phase delays, and occasionally regional left ventricular abnormalities. RV-delayed phase areas were always present in our population. A scoring system with RV criteria was proposed to diagnose RV disease. Because Fourier analysis of GBP SPECT provides ventricular morphologic information for the right ventricle with the same accuracy as for the left ventricle, it may replace planar radionuclide studies. Therefore, this method is helpful in patients with a strong clinical suspicion of arrhythmogenic RV cardiomyopathy, and should be used as a screening method before right ventriculography.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/1998
• Auteurs : Beatrice HechlerAnita Eckly-MichelPhilippe OhlmannJean-Pierre CazenaveChristian Gachet
• Organismes :
• Publié dans British Journal of Haematology le 29/10/2020

---

Résumé : Recently we showed that the P2Y1 receptor coupled to calcium mobilization is necessary to initiate ADP-induced human platelet aggregation. Since the thienopyridine compound clopidogrel specifically inhibits ADP-induced platelet aggregation, it was of interest to determine whether the P2Y1 receptor was the target of this drug. Therefore we studied the effects of clopidogrel and of the two specific P2Y1 antagonists A2P5P and A3P5P on ADP-induced platelet events in rats. Although clopidogrel treatment (50 mg/kg) greatly reduced platelet aggregation in response to ADP as compared to untreated platelets, some residual aggregation was still detectable. In contrast, A2P5P and A3P5P totally abolished ADP-induced shape change and aggregation in platelets from both control and clopidogrel-treated rats. A2P5P and A3P5P (100 microM) totally inhibited the [Ca2+]i rise induced by ADP (0.1 microM) in control and clopidogrel-treated platelets, whereas clopidogrel treatment had no effect. Conversely, the inhibition of adenylyl cyclase induced by ADP (5 microM) was completely blocked by clopidogrel but not modified by A2P5P or A3P5P (100 microM). A3P5P (1 mM) reduced the number of [33P]2MeSADP binding sites on control rat platelets from 907 +/- 50 to 611 +/- 25 per platelet. After clopidogrel treatment, binding of [33P]2MeSADP decreased to 505 +/- 68 sites per platelet and further decreased to 55 +/- 12 sites in the presence of A3P5P (1 mM). In summary, these results demonstrate that the platelet P2Y1 receptor responsible for the initiation of aggregation in response to ADP is not the target of clopidogrel. Platelets may express another, as yet unidentified, P2Y receptor, specifically coupled to the inhibition of adenylyl cyclase and necessary to induce full platelet aggregation, which could be the target of this drug.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/1998
• Auteurs : Pierre-André VuissozJean-Philippe AnsermetAndrzej Wieckowski
• Organismes : Ecole Polytechnique Fédérale de Lausanne
• Publié dans Electrochimica Acta le 02/11/2020

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 16/11/1998
• Auteurs : Jean-Claude DesportPierre-Marie PreuxCt TruongJean-Michel VallatD SautereauPhilippe Couratier
• Organismes : Neuroépidémiologie Tropicale et Comparée Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale et Comparée Service de Neurologie [CHU Limoges] Service de l'Information Médicale et de l'Évaluation [CHU Limoges] Laboratoire de Biostatistique et d'Informatique Médicale Centre de référence national neuropathies périphériques rares [CHU Limoges] Service de Neurologie [CHU Limoges] Neuroépidémiologie Tropicale et Comparée Service de Neurologie [CHU Limoges]

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/1998
• Auteurs : Laurent FauchierDominique BabutyMarie Laurence AutretPhilippe PoretPierre CosnayJean Paul Fauchier
• Organismes : Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours
• Publié dans Cardiovascular Drugs and Therapy le 29/10/2020

---

Résumé : Heart rate variability is a noninvasive indicator of autonomic nervous system activity. The role of the autonomic nervous system in the genesis of atrial or ventricular arrhythmias is now well established. Little is known about the effects of flecainide on heart rate variability in patients with normal heart structure, the main population receiving flecainide. This study was designed to evaluate the effects of flecainide on heart rate variability in patients without coronary artery disease or congestive heart failure. Time and frequency domain analysis of heart rate variability on 24-hour electrocardiogram recording were assessed in 40 patients with normal echocardiography and without evidence of coronary artery disease before and after 2 months of oral treatment with flecainide (321 +/- 57 mg/day) prescribed for Wolff Parkinson White syndrome with circus movement tachycardia. Flecainide significantly decreased all parameters of heart rate variability in the time domain (median delta% -10% to -25%) and in the frequency domain (median delta% -27% to -38%), including the markers of vagal activity. There was no correlation between plasma concentrations of flecainide and reduction in heart rate variability. It was concluded that in subjects without coronary artery disease or congestive heart failure, flecainide decreases all the measurements of heart rate variability and this decrease is not related to plasma concentrations of flecainide.

---

Source